Utility of established cardiovascular disease risk score models for the 10-year prediction of disease outcomes in women

Expert Review of Cardiovascular Therapy

Volumn 11, Issue 4, 2013, Pages 425-435

  Goh, Louise Gh ^a   Dhaliwal, Satvinder S ^a   Lee, Andy H ^a   Bertolatti, Dean ^a   Della, Phillip R ^a  

^a CURTIN UNIVERSITY   (Australia)

Author keywords

cardiovascular disease; mortality; prediction; risk; women

Indexed keywords

ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER;

ALCOHOL CONSUMPTION; ANTIHYPERTENSIVE THERAPY; ASSIGN RISK SCORE; CALIBRATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CORONARY ARTERY CALCIUM SCORE; DISEASE SEVERITY; EXTERNAL VALIDITY; FRAMINGHAM RISK SCORE; GENERAL CVD RISK SCORE; HUMAN; HYPERTENSION; INTERNAL VALIDITY; ISCHEMIC HEART DISEASE; OBESITY; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; PREDICTION; PREDICTIVE VALUE; PROGNOSIS; QRISK SCORE; RECEIVER OPERATING CHARACTERISTIC; REVIEW; REYNOLDS RISK SCORE; SCORE RISK CHART AND HEARTSCORE; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE;

ALCOHOL DRINKING; CALCINOSIS; CARDIOVASCULAR DISEASES; CORONARY VESSELS; EXERCISE; FEMALE; HUMANS; HYPERTENSION; MODELS, STATISTICAL; OBESITY; PREDICTIVE VALUE OF TESTS; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT;

EID: 84876113278     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.13.26     Document Type: Review

References (92)

1. Mackay J, Mensah G. The Atlas of Heart Disease and Stroke. WHO, Geneva, Switzerland (2004).
2. Rosamond W, Flegal K, Furie K et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117(4), e25-e146 (2008).
3. Engberding N, Wenger NK. Cardiovascular disease prevention tailored for women. Expert Rev. Cardiovasc. Ther. 6(8), 1123-1134 (2008).
4. Vaccarino V, Krumholz HM, Yarzebski J, Gore JM, Goldberg RJ. Sex differences in 2-year mortality after hospital discharge for myocardial infarction. Ann. Intern. Med. 134(3), 173-181 (2001).
5. Vaccarino V, Parsons L, Every NR, Barron HV, Krumholz HM. Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants. N. Engl. J. Med. 341(4), 217-225 (1999).
6. Mosca L, Linfante AH, Benjamin EJ et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation 111(4), 499-510 (2005).
7. Barrett-Connor EL. Obesity, atherosclerosis, and coronary artery disease. Ann. Intern. Med. 103(6 Pt 2), 1010-1019 (1985).
8. Wingard DL. Sex differences and coronary heart disease. A case of comparing apples and pears? Circulation 81(5), 1710-1712 (1990).
9. Welborn TA. The Busselton Study: Mapping Population Health (Cardiovascular and Respiratory Disease Risk Factors). Australasian Medical Publishing Company, Australia, 142 (1998).
10. Welborn TA, Cumpston GN, Cullen KJ, Curnow DH, McCall MG, Stenhouse NS. The prevalence of coronary heart disease and associated factors in an Australian rural community. Am. J. Epidemiol. 89(5), 521-536 (1969).
11. Cui Y, Blumenthal RS, Flaws JA et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch. Intern. Med. 161(11), 1413-1419 (2001).
12. Yusuf S, Hawken S, Ounpuu S et al.; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in countries (the INTERHEART study): case-control study. Lancet 364(9438), 937-952 (2004).
13. van Wijk DF, Boekholdt SM. Improving risk stratification for cardiovascular disease. Expert Rev. Cardiovasc. Ther. 8(8), 1091-1093 (2010).
14. Beswick A, Brindle P. Risk scoring in the assessment of cardiovascular risk. Curr. Opin. Lipidol. 17(4), 375-386 (2006).
15. British Cardiac Society, British Hypertension Society, Diabetes UK, Heart UK, Primary Care Cardiovascular Society, The Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 91(Suppl. 5), v1-v52 (2005).
16. De Backer G, Ambrosioni E, Borch- Johnsen K et al.; Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur. Heart J. 24(17), 1601-1610 (2003).
17. National Institutes of Health. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Final Report. (2002).
18. Ulmer H, Kollerits B, Kelleher C, Diem G, Concin H. Predictive accuracy of the SCORE risk function for cardiovascular disease in clinical practice: a prospective evaluation of 44,649 Austrian men and women. Eur. J. Cardiovasc. Prev. Rehabil. 12(5), 433-441 (2005).
19. Khot UN, Khot MB, Bajzer CT et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 290(7), 898-904 (2003).
20. Lowe LP, Greenland P, Ruth KJ, Dyer AR, Stamler R, Stamler J. Impact of major cardiovascular disease risk factors, particularly in combination, on 22-year mortality in women and men. Arch. Intern. Med. 158(18), 2007-2014 (1998).
21. Society of Actuaries. Build and Blood Pressure Study. Society of Actuaries, Chicago, IL, USA (1959).
22. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 97(18), 1837-1847 (1998).
23. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 83(1), 356-362 (1991).
24. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am. Heart J. 121(1 Pt 2), 293-298 (1991).
25. Cooney MT, Dudina A, De Bacquer D et al.; SCORE Investigators. How much does HDL cholesterol add to risk estimation? A report from the SCORE Investigators. Eur. J. Cardiovasc. Prev. Rehabil. 16(3), 304-314 (2009).
26. Conroy RM, Pyörälä K, Fitzgerald AP et al.; SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur. Heart J. 24(11), 987-1003 (2003).
27. Hosmer DW, Lemeshow S. Applied Logistic Regression. John Wiley & Sons, Inc, NJ, USA (2000).
28. Truett J, Cornfield J, Kannel W. A multivariate analysis of the risk of coronary heart disease in Framingham. J. Chronic Dis. 20(7), 511-524 (1967).
29. Walker SH, Duncan DB. Estimation of the probability of an event as a function of several independent variables. Biometrika 54(1), 167-179 (1967).
30. Pencina MJ, D'Agostino RB Sr, Larson MG, Massaro JM, Vasan RS. Predicting the 30-year risk of cardiovascular disease: the framingham heart study. Circulation 119(24), 3078-3084 (2009).
31. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285(19), 2486-2497 (2001).
32. Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur. Heart J. 18(12), 1231-1248 (1997).
33. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297(6), 611-619 (2007).
34. Berger JS, Jordan CO, Lloyd-Jones D, Blumenthal RS. Screening for cardiovascular risk in asymptomatic patients. J. Am. Coll. Cardiol. 55(12), 1169-1177 (2010).
35. Tunstall-Pedoe H, Woodward M, Tavendale R, A'Brook R, McCluskey MK. Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish Heart Health Study: cohort study. BMJ 315(7110), 722-729 (1997).
36. Woodward M, Brindle P, Tunstall-Pedoe H; SIGN group on risk estimation. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart 93(2), 172-176 (2007).
37. D'Agostino RB Sr, Vasan RS, Pencina MJ et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117(6), 743-753 (2008).
38. Hippisley-Cox J, Coupland C, Vinogradova Y et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 336(7659), 1475-1482 (2008).
39. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 335(7611), 136 (2007).
40. Cook NR. Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. Clin. Chem. 54(1), 17-23 (2008).
41. Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106(25), 3143-3421 (2002).
42. Koller MT, Steyerberg EW, Wolbers M et al. Validity of the Framingham point scores in the elderly: results from the Rotterdam study. Am. Heart J. 154(1), 87-93 (2007).
43. Siontis GC, Tzoulaki I, Siontis KC, Ioannidis JP. Comparisons of established risk prediction models for cardiovascular disease: systematic review. BMJ 344, e3318 (2012).
44. Mosca L, Benjamin EJ, Berra K et al.; American Heart Association. Effectivenessbased guidelines for the prevention of cardiovascular disease in women - 2011 update: a guideline from the American Heart Association. J. Am. Coll. Cardiol. 57(12), 1404-1423 (2011).
45. Marma AK, Berry JD, Ning H, Persell SD, Lloyd-Jones DM. Distribution of 10-year and lifetime predicted risks for cardiovascular disease in US adults: findings from the National Health and Nutrition Examination Survey 2003 to 2006. Circ. Cardiovasc. Qual. Outcomes 3(1), 8-14 (2010).
46. Dahlöf B. Cardiovascular disease risk factors: epidemiology and risk assessment. Am. J. Cardiol. 105(1 Suppl.), 3A-9A (2010).
47. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke. 22(3), 312-318 (1991).
48. McNeil JJ, Peeters A, Liew D, Lim S, Vos T. A model for predicting the future incidence of coronary heart disease within percentiles of coronary heart disease risk. J. Cardiovasc. Risk 8(1), 31-37 (2001).
49. Begg S, Vos T, Barker B, Stevenson C, Stanley L, Lopez AD. The Burden of Disease and Injury in Australia 2003. Australian Institute of Health and Welfare, Canberra, Australia (2007).
50. Mann JI, De Leeuw I, Hermansen K et al.; Diabetes and Nutrition Study Group (DNSG) of the European Association. Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus. Nutr. Metab. Cardiovasc. Dis. 14(6), 373-394 (2004).
51. Wilson PW, Bozeman SR, Burton TM, Hoaglin DC, Ben-Joseph R, Pashos CL. Prediction of first events of coronary heart disease and stroke with consideration of adiposity. Circulation 118(2), 124-130 (2008).
52. Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int. 73(1), 19-33 (2008).
53. National Health and Medical Research Council. Australian Guide to Healthy Eating. (2003).
54. Hu FB, Willett WC, Li T, Stampfer MJ, Colditz GA, Manson JE. Adiposity as compared with physical activity in predicting mortality among women. N. Engl. J. Med. 351(26), 2694-2703 (2004).
55. Welborn TA, Dhaliwal SS. Body-mass index and mortality among white adults. N. Engl. J. Med. 364(8), 781; author reply 781-783; author reply 783 (2011).
56. Welborn TA, Dhaliwal SS, Bennett SA. Waist-hip ratio is the dominant risk factor predicting cardiovascular death in Australia. Med. J. Aust. 179(11-12), 580-585 (2003).
57. Welborn TA, Dhaliwal SS. Preferred clinical measures of central obesity for predicting mortality. Eur. J. Clin. Nutr. 61(12), 1373-1379 (2007).
58. Dhaliwal SS, Welborn TA. Central obesity and multivariable cardiovascular risk as assessed by the Framingham prediction scores. Am. J. Cardiol. 103(10), 1403-1407 (2009).
59. Dhaliwal SS, Welborn TA. Central obesity and cigarette smoking are key determinants of cardiovascular disease deaths in Australia: a public health perspective. Prev. Med. 49(2-3), 153-157 (2009).
60. Dhaliwal SS, Welborn TA. Measurement error and ethnic comparisons of measures of abdominal obesity. Prevent. Med. 49(2-3), 148-152 (2009).
61. Shah T, Swerdlow D. Detecting, predicting and modifying cardiovascular risk: new and developing strategies. Expert Rev. Cardiovasc. Ther. 8(11), 1519-1521 (2010).
62. Thompson PD, Buchner D, Pina IL et al.; American Heart Association Council on Clinical Cardiology Subcommittee on Exercise, Rehabilitation, and Prevention; American Heart Association Council on Nutrition, Physical Activity, and Metabolism Subcommittee on Physical Activity. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 107(24), 3109-3116 (2003).
63. Blankenberg S, Zeller T, Saarela O et al.; MORGAM Project. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation 121(22), 2388-2397 (2010).
64. Shulman NB, Ford CE, Hall WD et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 13(5 Suppl.), I80-I93 (1989).
65. Sarnak MJ, Levey AS, Schoolwerth AC et al.; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108(17), 2154-2169 (2003).
66. Chobanian AV, Bakris GL, Black HR et al.; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289(19), 2560-2572 (2003).
67. National Kidney Foundation. K/DOQI clinical practice guidelines on managing dyslipidemias in chronic kidney disease. Am. J. Kidney Dis. 41(Suppl. 3), S1-S77 (2003).
68. Lakoski SG, Greenland P, Wong ND et al. Coronary artery calcium scores and risk for cardiovascular events in women classified as 'low risk' based on Framingham risk score: the Multi-Ethnic Study of Atherosclerosis (MESA). Arch. Intern. Med. 167(22), 2437-2442 (2007).
69. Yeboah J, McClelland RL, Polonsky TS et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA 308(8), 788-795 (2012).
70. Greenland P, Bonow RO, Brundage BH et al.; American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography); Society of Atherosclerosis Imaging and Prevention; Society of Cardiovascular Computed Tomography. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography) developed in collaboration with the Society of Atherosclerosis Imaging and Prevention and the Society of Cardiovascular Computed Tomography. J. Am. Coll. Cardiol. 49(3), 378-402 (2007).
71. D'Agostino RB, Griffith JL, Schmidt CH, Terrin N. Measures for evaluating model performance. Proceedings of: American Statistical Association, Biometrics Section. Alexandria, VA, USA, 253-258 (1997).
72. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143(1), 29-36 (1982).
73. Bamber D. The area above the ordinal dominance graph and the area below the receiver operating characteristic graph. J. Math. Psychol. 12(4), 387-415 (1975).
74. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat. Med. 27(2), 157-172; discussion 207 (2008).
75. Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat. Med. 23(13), 2109-2123 (2004).
76. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med. 15(4), 361-387 (1996).
77. Marcin JP, Romano PS. Size matters to a model's fit. Crit. Care Med. 35(9), 2212-2213 (2007).
78. Bertolini G, D'Amico R, Nardi D, Tinazzi A, Apolone G. One model, several results: the paradox of the Hosmer-Lemeshow goodness-of-fit test for the logistic regression model. J. Epidemiol. Biostat. 5(4), 251-253 (2000).
79. Murphy TP, Dhangana R, Pencina MJ, Zafar AM, D'Agostino RB. Performance of current guidelines for coronary heart disease prevention: optimal use of the Framingham-based risk assessment. Atherosclerosis 216(2), 452-457 (2011).
80. De Backer G. Prevention of cardiovascular disease in asymptomatic people. Heart 96(6), 477-482 (2010).
81. Marma AK, Lloyd-Jones DM. Systematic examination of the updated Framingham heart study general cardiovascular risk profile. Circulation 120(5), 384-390 (2009).
82. Tattersall MC, Karmali KN, Gangnon RE, Keevil JG. The population effects of the global cardiovascular risk model in United States adults: findings from the National Health and Nutrition Surveys, 2005-2006. J. Clin. Lipidol. 5(3), 166-172 (2011).
83. Greenland P, Alpert JS, Beller GA et al.; American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 122(25), e584-e636 (2010).
84. Cook NR, Paynter NP, Eaton CB et al. Comparison of the Framingham and Reynolds Risk scores for global cardiovascular risk prediction in the multiethnic Women's Health Initiative. Circulation 125(14), 1748-1756, S1 (2012).
85. West of Scotland Coronary Prevention Study. Influence of Pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97(15), 1440-1445 (1998).
86. Thomsen TF, McGee D, Davidsen M, Jørgensen T. A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. Int. J. Epidemiol. 31(4), 817-822 (2002).
87. Liu J, Hong Y, D'Agostino RB Sr et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi- Provincial Cohort Study. JAMA 291(21), 2591-2599 (2004).
88. Hense HW, Schulte H, Löwel H, Assmann G, Keil U. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany - results from the MONICA Augsburg and the PROCAM cohorts. Eur. Heart J. 24(10), 937-945 (2003).
89. Tunstall-Pedoe H. MONICA Monograph and Multimedia Sourcebook. WHO, Geneva, Switzerland, 124 (2003).
90. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P; CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 286(2), 180-187 (2001).
91. WHO. Cardiovascular diseases (CVDs) (2012). www.who.int/mediacentre/ factsheets/ fs317/en/index.html
92. Sign Scottish Intercollegiate Guidelines Network (2012). www.sign.ac.uk